20 YEARS OF PROFESSIONAL & DEDICATED SERVICE TO GLOBAL CUSTOMERS

Custom Manufacturing, Project Outsourcing, your Trusted Partner from China

Nilotinib Intermediate Synthesis: The Role of Ethyl 4-Methyl-3-((4-(Pyridin-3-yl)Pyrimidin-2-yl)Amino)Benzoate

Chronic Myelogenous Leukemia (CML) remains a significant focus in oncological research and treatment. The advent of targeted therapies, such as Nilotinib, has revolutionized patient outcomes. Central to the production of such advanced pharmaceuticals are high-quality intermediates, and among these, Ethyl 4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzoate, identified by its CAS number 641569-97-3, plays a pivotal role.

This complex organic molecule serves as a critical building block in the multi-step synthesis of Nilotinib. Its precise chemical structure and high purity are paramount to ensuring the efficacy and safety of the final drug product. Pharmaceutical manufacturers rely on a consistent supply of this intermediate to meet the global demand for Nilotinib, a tyrosine kinase inhibitor that effectively targets the BCR-ABL protein responsible for CML.

The synthesis of Ethyl 4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzoate involves intricate chemical reactions, demanding a deep understanding of organic synthesis principles. Manufacturers, particularly those specializing in pharmaceutical intermediates for cancer therapy, must adhere to stringent quality control measures. This includes ensuring a purity level of ≥98.0%, as even minor impurities can compromise the therapeutic effectiveness of the final API. For companies seeking a reliable supplier of this vital compound, focusing on manufacturers in China known for their expertise in fine chemical production is often a strategic choice.

Exploring the chemical properties, such as its off-white powder appearance and specific physical characteristics, further underscores its suitability for demanding pharmaceutical processes. The rigorous standards applied in its production directly translate to the quality of the life-saving medications it helps create. Understanding the nuances of Nilotinib intermediate synthesis, and the critical role of intermediates like CAS 641569-97-3, is essential for stakeholders in the pharmaceutical industry looking to advance cancer treatment solutions.

Manufacturing Facilities

NINGBO INNO PHARMCHEM CO.,LTD. was established in 2007. It is committed to the R&D, production and sales of raw materials, pharmaceutical intermediates and fine chemicals. We striving to create a high-efficiency and high-quality integrated chemical service platform to better serve domestic and foreign customers.

Professional Export Experience

to Global Customers

WHY CHOSE US?

1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;

2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;

3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).

FAQ

  • A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.

  • A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.

  • A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.

CONTACT US
Should you need to contact us; you may call during regular business hours, Monday through Friday, 8am – 6 pm.
NINGBO INNO PHARMCHEM CO.,LTD.
Address: No.163 Ruiqing Rd.,Ningbo 315000 China
Phone: 86-574-87319282
Fax: 86-574-27912196
SEND US AN EMAIL

NAME*

EMAIL*

COMPANY

COUNTRY*

MESSAGE*

Previous: Advanced Crosslinking: Enhancing Waterborne Coating Performance in China

Next: Sourcing High-Purity Pyrimidine Intermediates: A Guide for Pharmaceutical Manufacturers

All Rights Reserved